Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome

Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome

Co-stimulatory and inhibitory receptors expressed by immune cells in the tumor microenvironment modulate the immune response and cancer progression. Their expression and regulation are still not fully characterized and a better understanding of these mechanisms is needed to improve current immunothe...

Full description

Bibliographic Details
Main Authors: Véronique M. Braud, Jérôme Biton, Etienne Becht, Samantha Knockaert, Audrey Mansuet-Lupo, Estelle Cosson, Diane Damotte, Marco Alifano, Pierre Validire, Fabienne Anjuère, Isabelle Cremer, Nicolas Girard, Dominique Gossot, Agathe Seguin-Givelet, Marie-Caroline Dieu-Nosjean, Claire Germain
Format: Article
Language:English
Published: Taylor & Francis Group 2018-05-01
Series:OncoImmunology
Subjects:
llt1
cd161
non-small cell lung cancer
tertiary lymphoid structures
germinal center
tumor-infiltrating lymphocytes;
co-stimulatory receptor
th1 response
immune checkpoints
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1423184

Internet

http://dx.doi.org/10.1080/2162402X.2017.1423184

Similar Items